AstraZeneca Results Presentation Deck
Calquence and Enhertu
Calquence accelerated; Enhertu launch continued.
$m
200
150
100
50
0
Q1 2018
Q2 2018
Q3 2018
Calquence
Approvals: 51 (CLL¹) and 23 countries (MCL²)
Q4 2018
US Europe EROW EMS
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Total revenue at actual exchange rates.
14
Q1 2020
Q2 2020
Q3 2020
Q4 2020
●
●
●
Global $522m; US $511m
US CLL
Share of new patients:
Front line ~1/3 of BTKI³
class and ~10% overall
R/R >40% of BTKI class and
~20% overall4
Global CLL
Worldwide launch initiated;
EU approval
1. Chronic lymphocytic leukaemia 2. Mantle cell lymphoma (R/R)
3. Bruton tyrosine kinase inhibitor 4. IQVIA market research.
$m
40
30
20
10
US Europe
Q1 2020
Enhertu
Approvals: US, EU, Japan (mBC5); US, Japan (mGC6)
Q2 2020
Q3 2020
Q4 2020
Collaboration revenue at actual exchange rates.
●
●
Global $96m; US $93m
$200m in-market US sales
by Daiichi Sankyo; no. 1 in
3rd-line setting
Ex US
Europe: France early access
Japan: launched; royalty
00-406-41
ENHERTU
-rastrual dedica
100 mg per vial
nection
nu insion Onl
and Dute pro to
Cytotec Age
B
NDC 65597-406-01
Rx only
ENHERTUⓇ
(fam-trastuzumab deruxtecan-nxki)
For Injection
100 mg per vial
For Intravenous Infusion Only
Dispense the enclosed Medication Guide to each patient.
Reconstitute and Dilute prior to administration
Single-Dose Vial
Discard Unused Portion
CAUTION: Cytotoxic Agent
KEEP REFRIGERATED
1 vial
Daiichi-Sankyo AstraZeneca
5. Metastatic breast cancer (3L, HER2+) 6. Metastatic
gastric cancer (3L/2L+, HER2+).
4View entire presentation